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Diabetes mellitus is a public health problem worldwide. For this reason, ethanolic extract ofMiconia sp. fromOaxaca, Mexico, was
selected in search of an alternative against this disease.The effect ofMiconia sp. onmRNA expression of PPAR𝛾 on cell line 3T3-L1,
its effect on alpha amylase and alpha glucosidase, lipid accumulation during adipogenesis, and cell viability on VERO cells were
evaluated. The mRNA levels of PPAR𝛾 increased on 1.393 ± 0.008 folds, lipid accumulation was increased by 29.55% withMiconia
sp. extract and 34.57%with rosiglitazone, and 𝛼-amylase and 𝛼-glycosidase were inhibited with IC
50
values from 28.23±2.15 𝜇g/mL
and 1.95 ± 0.15 𝜇g/mL, respectively; the IC
50
on antiproliferative activity on VERO cells was 314.54 ± 45.40 𝜇g/mL. In case of 𝛼-
amylase and𝛼-glycosidase assays, IC
50
(inhibitory concentration 50) refers to necessary extract amounts to inhibit 50%of enzymatic
activity. On the other hand, on antiproliferative activity, IC
50
(inhibitory concentration 50) refers to necessary extract amounts to
inhibit 50% of cell proliferation. It was concluded that the compounds present in Miconia sp. ethanolic extract increase mRNA
expression of PPAR𝛾, inhibit 𝛼-amylase and 𝛼-glucosidase, and increase lipid accumulation. It constitutes an alternative as adjuvant
in diabetes mellitus treatment; therefore, we recommend continuing identifying the compounds responsible for its promising in
vivo antidiabetic activity.
1. Introduction
Diabetes mellitus is a chronic metabolic disease considered a
serious global public health problem. In 2010, approximately
285million people suffered from this disease and this amount
is expected to double up within the next 20 years [1]. Diabetes
mellitus type 2 (DM2) is the most common form of diabetes.
It is a complex metabolic alteration characterized by an
insulin combination resistance (IR, low sensitivity of one or
multiple tissues to insulin) and insulin secretion alteration
[2].
The search for new drugs that act against peroxi-
some proliferator-activated receptor gamma (PPAR𝛾) is very
important because ligands of these transcription factors
exhibit multiple biological responses such as decreasing the
IR and avoiding high levels of plasm glucose. It has been
shown that the adipogenesis process is under the control
of a complex cascade of transcriptional regulatory factors
in which PPAR𝛾 and other transcriptional factors of C/EBP
family play a fundamental role [3, 4].
Enzymes 𝛼-amylase and 𝛼-glucosidase found in saliva
and the brush border of the small intestine, respectively, act
on hydrolysis oligosaccharides and disaccharides to produce
easy absorption monosaccharides such as glucose. For the
above mentioned, delaying absorption of glucose through
inhibition of enzymatic hydrolysis of carbohydrates, carried
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out by alpha amylase and alpha glucosidase, could be another
form of combating DM [4].
About 80% of the population worldwide use medicinal
plants to treat various diseases. These constitute a major
source of drugs; about 25% of prescribed drugs worldwide
originate from plant species [5].
A species of the genre Miconia in Mexican traditional
medicine is used in south Mexico as an alternative for
diabetes mellitus treatment. However, such fact has not been
scientifically confirmed yet.Miconia is a genus of about 1000
species distributed in tropical America and belongs to the
Melastomataceae family, which has about 4300 species dis-
tributed in 166 genera. Very few studies on biological activity
have been performed on this genre, but it has been shown
that extracts and compounds isolated from species of the
genusMiconia have antibiotic, antitumor, analgesic, and anti-
malarial activities. A phytochemical analysis of methanolic
extract ofMiconia cabucu reveals the presence of glycosylated
flavonoids (quercetin, myricetin, and kaempferol all with
different glycosides), a tannin, and rare bioflavonoid. The
phytochemical research of M. rubiginosa extract led to the
identification of several glycosylated forms such as quercetin,
gallic acid, and epicatechin. Similarly, quercetin, myricetin,
and catechin derivativesM. stenostachya were found [6].
2. Materials and Methods
2.1. Preparation of the Extract. Miconia sp. aerial part was
collected in Oaxaca, Mexico. The plant was dried in shade
at room temperature and extraction with ethanol was per-
formed by the Soxhlet method (PYREX) for 48 h; solvent was
removed under reduced pressure using a rotary evaporator
(Yamato RE-200). Extract yield was determined and then
stored at room temperature until it was used.
2.2. Cell Culture Preparation and Adipocyte Differentiation.
Murine cell line 3T3-L1 preadipocytes were used. DMEM
medium supplemented with 10% fetal bovine serum (FBS)
was used for propagation; it was incubated at 37∘C at 5% CO
2
atmosphere, until reaching a confluence of 90%. The 100%
confluency was used for adipocyte differentiation. It could
be DMEM with 10% FBS, 1 𝜇M dexamethasone, 0.5mM 3-
isobutyl-1-methylxanthine, and 10 𝜇g/mL insulin (all brands
from Santa Cruz Biotechnology). After 48 hours of incuba-
tion (day 2), the differentiation medium was removed and
replaced every 48 hours until maturation of adipocytes (days
9–11), with maturation medium of adipocytes (DMEM with
10% FBS and insulin 10 𝜇g/mL called MM). The maturation
was confirmed by microscope observation of the typical
morphology of an adipocyte [7–10].
2.3. Expression of PPAR𝛾 in Adipocytes. The study was
performed in the cell line 3T3-L1 differentiated, follow-
ing the methodology described above, using microplate 6-
well culture with an inoculum of 100,000 cells per well
in a final volume of 2mL with the corresponding culture
medium. At day 10, adipocyte differentiation was observed
and replaced in the medium (MM).The following treatments
were added: Group 1: DMEM with 0.1% ethanol (expression
control group), Group 2: MM supplemented with 1 𝜇M of
rosiglitazone (positive control), Group 3: MM supplemented
with Miconia sp. extract (40 𝜇g/mL), and Group 4: MM
only to observe the effect of the medium. After 24 hours
of treatment application of the total RNA extraction, the
retrotranscription (cDNA) and PCR were performed in real
time to determine the effect on mRNA expression [8–10].
The total RNA isolation of treated adipocytes was per-
formed with an extraction kit SV Total RNA Isolation System
#Z3100, Promega (following themanufacturer’s instructions)
and stored at−80∘Cuntil use. Total RNA integrity, purity, and
quantification analysis was made in NanoDrop 8000 Spec-
trophotometer withThermo Scientific and an electrophoresis
gel (1.5% agarose).
CDNA synthesis was done with the ImProm-II Reverse
Transcription System kit Promega # A3800 with 500 ng of
RNA isolated. The cDNA was stored at −20∘C, until use.
Analysis of mRNA expression PPAR𝛾 was performed
by qRT-PCR using LightCycler 480 II Roche equipment,
and 50 ng of cDNA, 0.5 𝜇M of the primers, 12.5 𝜇L of
Maxima SYBRGreen qPCRMasterMix (2x) # K0251Thermo
Scientific, and the proper amount of nuclease-free water to
have a final volume of 25 𝜇L. The 36B4 was used [Thomson]
as reference gene. The sequence of the primers used is
PPAR𝛾 forward 5󸀠-CTGGCCTCCCTGATGAATAAAG-3󸀠,
reverse 5󸀠-AGGCTCCATAAAGTCACCAAAG-3󸀠, 36B4 for-
ward 5󸀠-ACTGGTCTAGGACCCGAGAAG-3󸀠, and reverse
5󸀠-TCAATGGTGCCTCTGGAGATT-3󸀠. The relative mRNA
expression was calculated based on the 2−ΔΔCt method.
2.4. Lipid Accumulation in Adipocytes. Lipid accumulation
was evaluated on the cell line 3T3-L1 using Oil Red O, with
modifications to the method described by other authors. The
method described above was used for cell differentiation.
Microculture plates were used having 24 wells with an
inoculum of 30,000 cells per well leading to a final volume
of 500𝜇L with culture medium. At 48 h after confluence
(day 0) the differentiation medium (Dm) was applied to
stimulate adipogenesis, supplemented with the substances to
be evaluated: treatment 1 [Dm (control reference)], treatment
2 [Dm supplementedwith 40𝜇g/mL extractMiconia sp.], and
treatment 3 [Dm supplemented with 1𝜇Mrosiglitazone (pos-
itive control)]. Subsequently, the microplate was incubated
for 48 h with the established conditions. After that, Dm was
replaced by MM (day 2) and incubated for 8 d. The culture
medium was removed, and formalin 10% was used for 1 h to
fix monolayer cells. After monolayer cells had been washed
twice with distilled water, the dye Oil Red O (0.5% in 60%
isopropanol) was applied for 15min at room temperature.The
cells were washed three times with distilled water; the dye
inside the cells was removed with 100% isopropanol and read
the optical density at 540 nm [9–12].
2.5. Inhibitory Activity of 𝛼-Amylase. The enzyme inhibition
was evaluated by the method of dinitrosalicylic acid 3,5-
(DNS) with some modifications. The Miconia sp. extract
was applied at different concentrations (25, 50, 75, 100,
and 125 𝜇g/mL) as a vehicle using phosphate buffer with
Evidence-Based Complementary and Alternative Medicine 3
20mM sodium 6.7mM sodium chloride, at pH 6.9. 𝛼-
Amylase enzyme (Sigma-Aldrich # A9857-250KU) was used
at 0.5U/mL concentration with the same buffer as a vehicle.
Starch 0.5% in phosphate buffer was used as a substrate.
Acarbose at different concentrations (312.5, 625, 1250, 2500,
and 5000 𝜇g/mL) was used as a positive control. Additionally,
DNS solution was used at 96mM. In 1.5mL conical tubes,
50𝜇L of substances was placed to be evaluated: treatment
1: Miconia sp. extracts, treatment 2: buffer phosphate with
2% ethanol (negative control), and treatment 3: acarbose
(positive control). Briefly, to the above treatments 50 𝜇L of
the 𝛼-amylase was added and incubated at 37∘C for 10min.
After that, to initiate the reaction, 50 𝜇L of the substrate
was added immediately and incubated at 37∘C for 15min.
Then, the reaction was stopped by adding 50 𝜇L of DNS and
heated in a water bath at 95∘C for 5min; the tubes were
left to cool at room temperature, and the optical density
was measured at 540 nm. The absorbance rates were used to
calculate the percent inhibition of each treatment using the
following equation:
% Inhibition = (Abs control − Abs treatment)
Abs control
× 100. (1)
In this equation, “Abs treatment” is the product’s light
absorption of the enzyme-substrate reaction in the presence
of the Miconia sp. or negative control as appropriate. “Abs
control” is the reaction product’s light absorption of enzyme-
substrate in the presence of phosphate buffer as a treatment.
The percentage inhibition using the statistical package (SPSS
v.20) allows us to calculate the inhibitory concentration: 50
(IC
50
) is the amount required to inhibit 50% of the enzyme
(Sigma-Aldrich # A8980-1G) [5, 13–15].
2.6. 𝛼-Glucosidase Inhibitory Activity. Inhibition of the
enzyme was evaluated by the pNPG method (p-nitrophenyl-
𝛼-D-glucopyranoside) with some modifications.Miconia sp.
extract at different concentrations (1, 2, 3, 4, and 5𝜇g/mL)was
used as a vehicle a buffer of sodium phosphate mentioned
above. Acarbose at different concentrations (62.5, 125, 250,
500, and 1000 𝜇g/mL) is positive control, using buffer sodium
phosphate as a vehicle. 𝛼-Glucosidase enzyme (Sigma-
Aldrich # G5003-100UN) at a concentration of 0.2U/mL
using phosphate buffer as a vehicle. Additionally, a prepara-
tion of pNPG 2mM (Sigma-Aldrich # N1377-1G) was used
as a substrate in the same vehicle. After that, in a 96-
well microplate, 25𝜇L of the substances was mixed with
the enzyme to the assay: treatment 1 [Miconia sp. extracts],
treatment 2 [phosphate buffer with 1% ethanol (negative
control)], and treatment 3 [acarbose (positive control)].
Besides the above treatments, 25𝜇L of the enzyme suspension
was added and incubated at 37∘C for 15min; immediately
after that, 50 𝜇L of pNPG was added and incubated at 37∘C
for 10min; then, the reaction was stopped by adding 50 𝜇L
sodium carbonate (0.2M).
Finally, the optical density at 405 nm was measured. The
absorbance rates were used to calculate the percent inhibition
of each treatment using the following equation:
% Inhibition = (Abs control − Abs treatment)
Abs control
× 100. (2)
In this equation, “Abs treatment” is the product’s light
absorption of the enzyme-substrate reaction in the presence
of the Miconia sp., acarbose or negative control as appro-
priate. “Abs control” is the product’s light absorption of
the enzyme-substrate reaction in the presence of phosphate
buffer as a treatment. Percent inhibitions using a statistical
package (SPSS v.20) were used to determine the inhibitory
concentration 50 (IC
50
) that is the amount of treatment
necessary to inhibit the enzyme 50% [4, 13–15].
2.7. Cell Proliferation Assay. Cell proliferation with MTT
colorimetric method (3-(4,5-dimethylthiazol-2-y1)-2,5-
diphenyltetrazolium bromide) was evaluated.The VERO cell
(monkey kidney epithelial) lines are widely used in research
to evaluate the effect of chemicals and toxins in mammals
[16]. 1 × 105 cells/well were seeded in a 96-well microplate and
adjusted to a final volume of 200𝜇L with culture medium
(DMEM supplemented with 10% FBS) and incubated at
37∘C in an atmosphere of 5% CO
2
. After 24 h and until
reaching a layer of 80% confluence, the culture medium
was removed and cells were washed with phosphates (PBS),
a buffered saline solution; further substances were added
and evaluated: treatment 1 [extracts of Miconia sp. (62.5,
125, 250, 500, and 1000 𝜇g/mL)], treatment 2 [DMEM with
1% ethanol (negative control)], and treatment 3 [cells with
culture medium (reference of proliferation)]. After that, the
microplate was incubated for 24 h at the above conditions.
Then, 10 𝜇L MTT (5mg/mL) were added to each well and
incubated again for 4 h; the culture medium was removed
and cells were washed with PBS. Immediately afterwards,
200𝜇L dimethyl sulfoxide (DMSO) was added; then the
optical density was measured at 570 nm. By the following
formula the percentage of cell proliferation was determined:
% cell proliferation = Abs treatment
Abs control
× 100. (3)
In this equation, “Abs treatment” is the product’s light absorp-
tion of the treated cells and “Abs control” is the product’s light
absorption of cells used as proliferation reference.The IC
50
is
calculated with the percentages of cell proliferation and with
the support of SPSS v.20 [17, 18].
3. Results
In this study, different biological activities of ethanolic extract
of Miconia sp. were evaluated in their effect on expression
of mRNA PPAR𝛾, lipid accumulation during adipogenesis,
the activity of 𝛼-amylase and 𝛼-glucosidase, and the effect on
proliferation of VERO cell line.
In determining the expression level ofmRNAof PPAR𝛾 in
mature mouse adipocytes, Group 1 was used as an expression
control, which was normalized to a value of 1. Therefore, the
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Figure 1: Effect of different compounds on the expression of mRNA
PPAR𝛾. On day 10 the treatments were applied; Group 1: DMEM
with 0.1% ethanol (EC), Group 2: MM and rosiglitazone (Ros) as
a positive control, Group 3: MM and Miconia (Mic), and Group
4: MM. On day 11 of adipocyte differentiation the total RNA was
isolated. ∗𝑃 ≤ 0.05: there is a significant difference with the control
of expression; ∗∗𝑃 ≤ 0.05: there is a significant difference with the
control of expression and rosiglitazone (𝑛 = 3).
values above 1 indicate an overexpression or upregulation. In
Group 2 the value in the expression levels was 1.166 ± 0.007
fold change; at the same time, in Group 3 a value was 1.393 ±
0.008 and finally Group 4 showed a value of 0.746±0.034 fold
change (Figure 1).
Miconia sp. 40 𝜇g/mL produced upregulation in the
expression of mRNA of PPAR𝛾 with a value greater than
that of the drug rosiglitazone, which increases the expression
of PPAR𝛾 as expected. The use of maturation medium with
both extracts as rosiglitazone did not increase by itself the
expression levels of the gene PPAR𝛾.
In the lipid accumulation test during adipogenesis with
different treatments, Group 1 (Dm) showed absorbance of
0.137; this value represents the accumulated lipids during
adipogenesis induced differentiation medium already estab-
lished. At the same time, Group 2 (Dm + Miconia sp.
40 𝜇g/mL) showed absorbance of 0.184; Group 3 (Dm +
rosiglitazone 1 𝜇M) showed an absorbance value of 0.177.
Taking the absorbance value from Group 1 as 100% lipid
accumulation, when extract Miconia sp. was added to the
differentiation medium, lipid accumulation was increased to
34.57% compared to Group 1. Like the Miconia sp. extract,
adding the drug rosiglitazone to differentiation medium, it
causes an increase of 29.55% compared to Group 1. The
increased absorbance of the extract and the drug is significant
compared with Dm; Miconia sp. presented a very similar
result to rosiglitazone, difference between them not of great
significance (Figure 2).
In the 𝛼-amylase inhibition assay, different treatments
to the mixture of enzyme-substrate reaction were added,
obtaining the following results: for treatment 1, Miconia sp.
presented IC
50
of 28.23 ± 2.15 𝜇g/mL. At the same time,
for treatment 2, phosphate buffer and 2% ethanol (negative
control) showed no inhibition by the vehicle used; for
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Figure 2: Effect of different substances in lipid accumulation during
adipogenesis in 3T3-L1 cells.The treatments were applied at day 0 of
differentiation and withdrawn at day 2. On day 10 when adipocytes
reached maturity, the staining was performed. ∗𝑃 ≤ 0.05 significant
difference between treatments and Dm (𝑛 = 3).
Table 1: Enzymatic inhibition from acarbose and Miconia sp.
extract.
Treatment
𝛼-Amylase
(IC
50
± DE
𝜇g/mL)
𝛼-Glucosidase
(IC
50
± DE
𝜇g/mL)
Miconia∗ 28.23 ± 2.15 1.95 ± 0.15
Acarbose (positive control) 993.84 ± 157.13 331.00 ± 72.08
Phosphate buffer with 1%
ethanol (negative control) NI NI
Data are expressed as mean ± the SD (𝑛 = 3). NI: no inhibition. ∗𝑃 ≤ 0.05
significant difference with acarbose.
treatment 3: acarbose presented IC
50
of 993.84±15.13 𝜇g/mL
(positive control).
According to the results and despite being a complete
extract, the extract of Miconia sp. reveals a greater capacity
than acarbose to inhibit 50% of enzyme activity; this differ-
ence between the two treatments is statistically significant
(Table 1).
In the inhibition assay of 𝛼-glucosidase, the following
results were obtained: for treatment 1, Miconia sp. extract
provided IC
50
of 1.95 ± 0.15 𝜇g/mL. At the same time, for
treatment 2, phosphate buffer with 1% ethanol (negative
control) did not show any inhibitory effect on the enzyme;
for treatment 3, acarbose (positive control) showed IC
50
of
331.00 ± 72.08 𝜇g/mL (Table 1).
Miconia sp. extract also has a greater inhibition than
acarbose, and acarbose is used as a reference compound in the
inhibition of these enzymes.The differences in the treatments
are statistically significant.
In determining the proliferation on the VERO cell line,
IC
50
of 314.54 ± 45.40mg/mL considered toxic was obtained
forMiconia sp. extract.
4. Discussion
PPAR𝛾 is a nuclear receptor that acts as a transcription factor;
it improves insulin sensitivity by the cells and enhances
Evidence-Based Complementary and Alternative Medicine 5
glucose utilization [19]. A diverse set of natural and synthetic
molecules is classified as ligands and can induce activation
and that expression of PPAR𝛾. These ligands include nutri-
ents, endogenous ligands, and drugs [20]; one of those drugs
is thiazolidinediones (TZDs), such as rosiglitazone. Miconia
sp. showed an increased mRNA expression of PPAR𝛾, even
more than rosiglitazone. Moreover, Miconia sp. was able
to increase lipid accumulation during adipogenesis in 3T3
cell line L-1 similar to positive control rosiglitazone. It is
known that PPAR𝛾 is the master regulator of adipocyte
differentiation, and during adipogenesis PPAR𝛾 is induced
[21]. PPAR𝛾 activation in adipocytes ensures proper balance
and secretion of adipokines, such as leptin and adiponectin;
they are mediators in insulin action in peripheral tissues,
which causes insulin sensitivity throughout the body [22].
The products mentioned above that stimulate the production
of PPAR𝛾 are candidates to induce the proper functioning
of insulin and recognition, considering them as potential
antidiabetic agents.
The results suggest that the presence of secondary
metabolites could be involved in upregulation of PPAR𝛾 gen.
Quercetin, catechin, and kaempferol have been reported in
some species of Miconia sp. and these compounds could act
as ligands of PPAR𝛾 [6, 21] just as rosiglitazone does. Some
TZDs as rosiglitazone have been associated with a significant
increase of cardiovascular diseases. For this reason, FDA
restricted their prescription in the United States [23].
Avoiding the increase of postprandial glucose is impor-
tant to keep the glycemic levels low in diabetic patients.
The inhibition of 𝛼-amylase and 𝛼-glucosidase present in
the gastrointestinal tract could keep the levels of glycemia
low. Drugs inhibit these enzymes, such as acarbose, miglitol,
voglibose, nojirimycin, and 1-deoxynojirimycin, which allow
the slow absorption of carbohydrates [23]. The ethanolic
extract of Miconia sp. inhibits 𝛼-amylase by 50% to a less
concentration than the acarbose drug. Additionally, the 𝛼-
glucosidase is inhibited byMiconia sp. at low concentrations,
lower than the drug. Therefore, it is believed that in the
presence of molecules with antihyperglycemic effect in in
vitro model, these compounds could be an alternative to
existing treatments or adjunctive to them, which may have
undesired side effects.
Miconia sp. showed cytotoxicity at a greater concentration
than necessary to increase expression of PPAR𝛾, increase
lipid accumulation, and inhibit 𝛼-glucosidase and 𝛼-amylase.
There are reports that the species of the genus Miconia,
M. stenostachya, M. cabucu, M. albicans, and M. rubiginosa,
lack cytotoxicity or mutagenicity at lower concentrations of
100 𝜇g/mL [6].
5. Conclusions
The ethanolic extract of Miconia sp. showed increase of the
level of mRNA expression of PPAR𝛾 at a significantly higher
level than rosiglitazone (drug). Also, Miconia sp. showed
inhibition of the enzymes 𝛼-glucosidase and 𝛼-amylase with
IC
50
lower than acarbose (drug) and furthermore increase the
capacity of lipid accumulation during adipogenesis, similar to
the drug rosiglitazone. At the same time,Miconia sp. showed
cytotoxicity on VERO cells with a concentration higher
than that presenting biological activity. For this reason, the
compounds present in the ethanolic extract ofMiconia sp. can
be an alternative for the treatment of diabetes mellitus or like
an adjunctive, with the recommendation of continuing with
in vivo tests and elucidation of bioactive compounds.
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